AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05929599 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo Navax
Description: In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
Study NCT06192485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: proactive balance training
Description: 20 participants will receive a proactive balance training program
Study NCT06192485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reactive balance training
Description: 20 participants will receive a Reactive balance training program
Study NCT05050149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-022
Description: Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
Study NCT06510842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External drainage of intraventricular hemorrhage
Description: An EVD is required to be eligible for the DRAIN IVH study. Weaning from the EVD is at the discretion of the local investigators. Imaging is at discretion of local investigators. Use, timing and frequency of fibrinolysis via EVD is at local discretion, too.
Study NCT06510842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External drainage of intraventricular hemorrhage
Description: An EVD is required to be eligible for the DRAIN IVH study. Weaning from the EVD is at the discretion of the local investigators. Imaging is at discretion of local investigators. Use, timing and frequency of fibrinolysis via EVD is at local discretion, too.
Study NCT05898412 — intervention group
Intervention type: DRUG
Intervention: Andexanet alfa
Description: Patients treated with andexanet alfa
Study NCT04169243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Nordic Diet
Description: The New Nordic Diet conforms with the Nordic Nutrition Recommendations and incorporates environmental sustainability and planetary health. It includes rapeseed oil, whole grain bread, wild fish, seafood and game, potatoes, root vegetables, cabbages, Nordic fruits and berries. A two-week menu including all daily meals has been created to ensure dietary goals of the New Nordic Diet intervention: fish and shellfish intake ≥ 3 times/w (fatty fish at least once per week), ≥ 500 g fruit, berries, vegetables and legumes daily (legumes as main protein source at least twice per week), whole-grain cereal products, rapeseed oil for cooking/dressing and three table spoons of nuts and seeds per day.
Study NCT04169243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control women receive diet advice according to usual care, which may be a short meeting with the regular midwife or a short meeting with a dietician. From the study, they will receive a gift certificate that can be used in grocery stores.
Study NCT06393062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.
Description: Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.
Study NCT05288322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mostafa Maged maneuver
Description: The Mostafa Maged maneuveur has been applied to those all female patients to prevent or control post-partum bleeding in normal delivery . The Mostafa Maged technique is applied by :- (Description of the new Mostafa Maged technique) :-~1. First , placing our right hand to the posterior fornix of vaginal canal trying to cuddle the lower part of uterus compressing the anterior and posterior walls of the uterus .~2. Second , placing our left hand over the fundus of the uterus and the posterior wall of uterus from the abdominal part.~3. Third , by our two hands , trying to grasp the whole uterus by our two hands abdominally and vaginally against the symphysis pubis as if the uterus is cuddling the symphysis pubis bone and in this way , we try to get the anterior and posterior walls against each other and reducing the intra-cavitary space so we prevent the expansion of the uterus .
Study NCT05537948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of Pitavastatin: Pitavastatin at visit 0 will be prescribed at a dose of 2 mg, after 1 month in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg.~The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with pitavastatin, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). There will be visits on the 7th, 9th and 12th months.
Study NCT05537948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCSK9 inhibitor
Description: First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of PCSK9 inhibitors:The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with a PCSK9 inhibitor, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). Pitavastatin will initially be prescribed at a dose of 2 mg, after 1 month. in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg. There will be visits on the 7th, 9th and 12th months.
Study NCT06298331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise training will be given for 8 weeks, 3 days a week on the treadmill in the clinic under the supervision of a physiotherapist, and 8 weeks, the other 2 days a week outside the clinic. The duration of the walking session is 50 minutes (5 minutes warm-up - 40 minutes load - 5 minutes cool down). Walking speed in the clinic will be determined according to the Heart Rate Reserve(HRR) method. In the warm-up and cool-down phases in the clinic, the walking speed will be adjusted in the range of 20-40% of HRR, while in the loading phase it will be adjusted in the range of 40-60% of HRR. Heart rate will be monitored with a monitor that detects heart rate by hand contact on the treadmill. Outside the clinic, walking speed will be determined according to the level of fatigue perceived on the Borg Scale. Outside the clinic, walking speed will be regulated as 10-12 (light) on the Borg scale during warm-up and cool-down phases and 12-14 (slightly difficult) during the loading period.
Study NCT06298331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Massage
Description: Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage.
Study NCT06298331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Massage
Description: Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage.
Study NCT06298331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: Patient education will include information on the definition of constipation, causes of constipation, how constipation occurs, factors affecting constipation, concepts related to constipation, treatment options for constipation, and lifestyle recommendations for constipation, including increasing fluid intake, regulating nutrition, increasing physical activity, and regulating toilet habits.
Study NCT06298331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patient education will include information on the definition of constipation, causes of constipation, how constipation occurs, factors affecting constipation, concepts related to constipation, treatment options for constipation, and lifestyle recommendations for constipation, including increasing fluid intake, regulating nutrition, increasing physical activity, and regulating toilet habits.
Study NCT06469216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Hyaluronic Acid to be used as sodium hyaluronate powder plus inactive ingredient (Carboxy methyl cellulose) and to be dissolved in distilled water
Study NCT06469216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient (Carboxy methyl cellulose) to be used as powder and to be dissolved in distilled water
Study NCT05936580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuwiq
Description: Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
Study NCT06065657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Supplement
Description: Ketone supplement 3x day with control diet for 3 days.
Study NCT06065657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: Control Diet breakfast, lunch, and dinner for 3 days.
Study NCT06065657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic Diet breakfast, lunch, and dinner for 3 days.
Study NCT06065657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Description: After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
Study NCT06065657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
Study NCT05583721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13N]NH3
Description: Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
Study NCT05583721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexiscan
Description: Given IV prior to PET stress test
Study NCT05583721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.
Study NCT05687500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Description: Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
Study NCT05687500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics study
Description: 0.2 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.~PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant ,apparent clearance and volume of distribution
Study NCT05687500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-peptide proinsulin ratio
Description: blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio
Study NCT05687500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood glucose on fluorinated tube
Description: 0.3 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.
Study NCT05687500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine biological monitoring
Description: If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.
Study NCT05687500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: glycose holter monitor
Description: glucose levels will be collected with a smarter continuous glucose monitoring system, placed on inclusion and until the end of treatment
Study NCT05696626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene in combination with abemaciclib
Description: 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
Study NCT05696626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant in combination with abemaciclib
Description: Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
Study NCT06565780 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Device under test evaluation against references
Description: Subjects will be asked to stay seated while blood pressure and pulse rate measurements are taken at different timepoints with the device under test and references.~Device under Test: Aktiia.product-G0 References: Cuff for double auscultation for blood pressure and Electrocardiogram for pulse rate.
Study NCT04933539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone PO/IV (for Cycles 1-4: Dexamethasone 40 mg IV/PO on days 1, 8, 15, 22; for Cycles =5: Dexamethasone 20 mg IV/PO on days 1, 8, 15, 22); for up to 12 cycles
Study NCT04933539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib IV (for Cycles 1-2: 20 mg/m2 IV on day 1, 56 mg/m2 IV on days 8, 15; Cycles =2: 56/m2 IV on days 1, 8, 15); for up to 12 cycles
Study NCT04933539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab SC 1800 mg (Cycles 1-2: Days 1, 8, 15, 22; Cycles 3-6: Days 1, 15; Cycles =7: Days 1 of the 28-day cycle); up to 36 cycles total
Study NCT04758624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Medtronic Activa device will be implanted and administered clinically, except as part of the trial after 24 months of DBS being on it will be turned off for 3 days and will be turned back on.
Study NCT05500417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALFQ
Description: ALFQ (Army Liposome Formulation containing QS-21) is composed of ALF55 (cGMP-manufactured Army Liposome Formulation), QS-21 (purified extracted saponin), and Sorensen's Phosphate Buffer. Full dose of AFLQ compromised of 200 microgram 3D-PHAD and 100 microgram QS-21, co-administered with main intervention.
Study NCT05500417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJCV2
Description: Vaccine comprised of C. jejuni capsule conjugated to Cross-Reactive Material 197 (CRM197), a non-toxic mutant protein of diphtheria toxin. CJCV2 will be reconstituted in 1 mL of sterile water for injection (SWI). The resuspended CJCV2 product will be diluted with sterile 0.9% Sodium Chloride for Injection. 3 dosages for administration: 1 microgram, 3 micrograms, and 10 micrograms.
Study NCT06569056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-8427
Description: Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
Study NCT06569056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem and Cilastatin Sodium
Description: Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
Study NCT06569056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRS-8427 placebo
Description: Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
Study NCT06569056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem and Cilastatin Sodium placebo
Description: Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
Study NCT05814055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants on this arm will take one placebo capsule orally three times daily for 4 weeks.
Study NCT05814055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-free kava
Description: Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 4 weeks.
Study NCT06536491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-104 high dose
Description: Intravitreal injection
Study NCT06536491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-104 low dose
Description: Intravitreal injection
Study NCT06536491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intravitreal implant
Description: Marketed product intravitreal injection
Study NCT06355440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Navigation
Description: One-on-one information support with material booklets during hospitalization. Weekly financial navigation information will be sent via WeChat after discharge for 1 month.~The financial navigation encompasses comprehensive information support:~* Strategies on patient-physician costs discussion~* Skills for inquiring and tracking treatment-related costs~* Basic knowledge about health insurance~* Guidance on accessing and applying for financial assistance~* Suggestions for returning to normal life and work~* Strategies for holding a financial-related family meeting
Study NCT06355440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive usual oncology care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support.
Study NCT05415462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection
Study NCT05415462 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Tetra
Description: Sterile suspension for injection
Study NCT06384027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation
Description: Ventilation support that does not require an artificial airway that aims to reverse respiratory muscle fatigue and decrease the work of the respiratory muscles, maintaining a positive pressure, allows alveolar recruitment, preventing atelectasis and airway collapse. NIV can be administered using continuous positive airway pressure (CPAP) or two levels of airway pressure (Bi-level).
Study NCT06085547 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General SARS-CoV-2 Communication
Description: SARS-CoV-2 video tutorial is for general consumption and does not include rural-targeted information
Study NCT05989204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TmCD19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
Study NCT06085547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rural-Targeted SARS-CoV-2 Communication
Description: SARS-CoV-2 video tutorial includes a two and a half minute video based messaging adjunct meant to enact a rural-targeted framing of health information presented to White rural individuals.
Study NCT06504459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT06504459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06504459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy
Study NCT06504459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT06504459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT06504459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC
Study NCT06504459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06504459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo LP
Study NCT06504459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06504459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies